CORC

浏览/检索结果: 共16条,第1-10条 帮助

限定条件                
已选(0)清除 条数/页:   排序方式:
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer 期刊论文
2019, 卷号: 30, 期号: 4, 页码: 558-566
作者:  Robson, M. E.;  Tung, N.;  Conte, P.;  Im, S-A;  Senkus, E.
收藏  |  浏览/下载:8/0  |  提交时间:2020/01/03
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文
EUROPEAN JOURNAL OF CANCER, 2018-04-01
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载:16/0  |  提交时间:2020/01/03
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文
2018, 卷号: 92, 页码: S19-S20
作者:  Senkus-Konefka, E.;  Domchek, S. M.;  Im, S. A.;  Xu, B.;  Armstrong, A.
收藏  |  浏览/下载:8/0  |  提交时间:2020/01/03
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 期刊论文
2018, 卷号: 78, 期号: 4
作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe
收藏  |  浏览/下载:6/0  |  提交时间:2020/01/03
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD 会议论文
CANCER RESEARCH, 2018-02-01
作者:  Domchek, Susan M.;  Robson, Mark;  Im, Seock-Ah;  Senkus, Elzbieta;  Xu, Binghe
收藏  |  浏览/下载:8/0  |  提交时间:2020/01/03
Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer 会议论文
ANNALS OF ONCOLOGY, 2018-10-01
作者:  Liu, Y-Z.;  Hodgson, D.;  Locker, G.;  Lai, Z.;  Balcerzak, D.
收藏  |  浏览/下载:5/0  |  提交时间:2020/01/03
Olaparib plus paclitaxel sensitivity in biomarker subgroups of gastric cancer 期刊论文
2018, 卷号: 29, 页码: 25-26
作者:  Liu, Y-Z.;  Hodgson, D.;  Locker, G.;  Lai, Z.;  Balcerzak, D.
收藏  |  浏览/下载:4/0  |  提交时间:2020/01/03
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03
OlympiAD: Further efficacy outcomes in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's choice 会议论文
ANNALS OF ONCOLOGY, 2017-09-01
作者:  Delaloge, S.;  Conte, P. F.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03
OlympiAD: Health-related quality of life (HRQoL) in patients with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard single-agent chemotherapy treatment of physician's cho 期刊论文
2017, 卷号: 28
作者:  Robson, M.;  Ruddy, K. J.;  Im, S-A.;  Senkus-Konefka, E.;  Xu, B.
收藏  |  浏览/下载:3/0  |  提交时间:2020/01/03


©版权所有 ©2017 CSpace - Powered by CSpace